NEWS
SUBSCRIBER SEARCH (Requires Login)
  NEW DRUGS
  MARKETED DRUGS
  COMPANY
  TARGETS IN ONCOLOGY
  NEWS SUMMARIES
  COMBINATION TRIALS

Latest Updates

Second Quarter 2010 New Drug Updates and Additions

Designation

Brand Name

Generic Name

 

AMEP

 

 

Aplidin R (Aplidine)

Plitidepsin, dehydrodidemnin B

 

ATT (Apoptosis Targeted Therapy)

 

 

BiovaxID

 

 

Doxorubicin (Doxorubicine) Transdrug

Doxorubicin

 

Reolysin (formerly Reosyn)

 

 

SB1518, ONX0803

 

 

Silybin

Silibinin

 

StemEX

Carlecortemcel-l

124-Iodine-cG250 (124I-cG250), CAN9-SCAN, WX/20-001

Redectane

 

ABR-215050

TASQ

Tasquinimod

ABT-263, RG7423

 

Navitoclax

ABT-888, NSC 737664

 

Veliparib

Actinium-225-HuM195, HuM195-Ac-225

 

 

ADI-PEG, ADI-PEG-20, ADI-PEG-SS 20,000 mw

 

 

ADXS11-001, Lm-LLO-E7

Lovaxin C

 

AG-003, AGS-003

Arcelis

 

ALS-357

 

Betulinic acid

AMG-386, AMG386, AMG 386

 

 

AMG706, AMG-706

 

Motesanib diphosphate

AN-152, AN 152, ZEN-008, AEZS-108

 

Doxorubicin

Anti-PlGF, TB-403, TH403, RG7334

 

 

ANX-510

CoFactor

Fotrexorin

ANX-530, formerly SDP-012

Exelbine

Vinorelbine tartrate

AP23573, MK-8669

 

Ridaforolimus (formerly deforolimus)

AP5346

ProLindac

APC8024, BA7072

Neuvenge

Lapuleucel-T

Aplidin R (Aplidine)

 

Plitidepsin, dehydrodidemnin B

AR119, RDEA119

 

 

ARQ-650RP, ARQ 650RP, ARQ 197, ARQ197

 

 

ARRY-334543, ARRY-543

 

 

ARRY-380, ARRY-333786

 

 

ARRY-520

 

 

ARRY-614

 

 

ARRY-704, AZD8330

 

 

ART010

 

 

AS1413, NSC 308847

Formerly Xanafide

Amonafide L-malate

Atu027/Atu093

 

 

AV-299, SCH900105

 

 

AV-951, formerly KRN951

 

Tivozanib

AVL-292

 

 

AZD2171, AZD 2171, NSC-732208

Recentin

Cediranib

AZD6244, ARRY-142886, ARRY-886

 

 

BAY 57-9352

 

Telatinib

BIIB022

 

 

BKT-140

 

 

BLX-301

 

 

BMN-673, LT-673

 

 

BMS-582664

 

Brivanib alalinate

BMS-754807

 

 

BP-100-1.01, L-Grb2, Grb-2

 

 

CAL-101

 

 

CAP-232, TT-232, TLN-232

 

 

carbonic anhydrase (CA) IX (CA9 or MN) antigen vaccine

 

 

carcinoembryonic antigen (CEA) vaccine

 

 

CDX-110, ALT-110, PF-4948568

 

 

CDX-1127

 

 

CGC-11047, PG-11047, SL-11047

 

 

CGC-11093

 

 

CGC-11102, CGC-11157, CGC-11217, CGC-11294

 

 

CP-4055

Elacyt

Ara-C, elacytarabine

CP-4126, CO-1.01

 

Gemcitabine 5'-elaidic acid ester

CP-4200

 

5-Azacitidine (AzaC)

CP-751871, CP-751,871

 

Figitumumab

CRS-207

 

 

CS7017, CS-7017

 

 

CUDC-101

 

 

Cur-691, GDC-0449, RG3616

HhAntag

 

CYT387

 

 

D-24851, ZIO-301

Zybulin

Indibulin

D3263, D-3263

 

 

DOX-LTSL

ThermoDox

Doxorubicin

DPX-0907

 

 

E7389, NSC-707389 (formerly ER-086526)

 

Eribulin mesylate

EG009, ad.HSV tk

Cerepro

 

EG01257

 

 

ENMD-981693, ENMD-2076

 

 

EPO906

Patupilone

 

F50035, MK-0646, MK0646

 

Dalotuzumab

GA101, RO5072759, RG7159

GlycoMAb

 

GAP-107B8 , PhGalpha1, PhGalpha-1

 

 

GDC-0152

 

GVAX leukemia vaccine, GM-K562, GVAX CML

 

 

GVAX prostate cancer vaccine, CG1940/CG8711

 

 

HKI-272

 

Neratinib

HKI-357

 

 

HuM195/rGel

 

 

HuMax-CD38

 

 

HYB2055, IMO-2055, EMD 1201081

IMOxine

 

ICT-107

 

 

IMC-A12, NSC-742460

 

Cixutumumab

IMMU-103, hLL2, hCD22, AMG 412

LymphoCide

Epratuzumab

IMMU-106, hA20, hCD20

 

Veltuzumab

INSM-18

 

 

IPP-204106, Nucant 6L

 

 

IRX-2

 

Citoplurikin

JX-594

 

 

KRX-0401, D-21266

 

Perifosine

L-BLP25, BLP-25 (formerly BP1-7-KLH)

Stimuvax

 

LBH 589, LBH589, NVP-LBH589, LBH489B, LBH489A

 

Panobinostat

LEP-ETU (formerly PNU-93914)

 

Paclitaxel

Liposome Entrapped Docetaxel for Injection (LE-DT)

 

Docetaxel

LOR-253, ML-220, ML-series (ML-133 and LT-253)

 

 

MDX-010, MDX-CTLA4; BMS-734016

 

Ipilimumab

MDX-1307, HCG-VAC, CDX-1307

 

 

MEDI-573

 

 

MGCD0103

 

Mocetinostat

MGCD265

 

 

MGN1601

 

 

MKC1106-PP, MKC-1106

 

 

MOR 202, MOR202

 

 

NBI-56418

 

Elagolix

NPC-1C

 

Ensituximab

NPI-2350 and NPI-2358

 

 

NS-187, INNO-406, CNS-9

 

Bafetinib

NSC-649890, L86-8275, HMR-1275, HMR1275

 

Alvocidib, flavopiridol

OMP-18R5 and others

 

 

OMP-21M18

 

 

ON 013105

 

 

ON 01910.Na, ON01910.Na, ON01910

Estybon

 

ON 24160

 

 

OncoVEX GM-CSF, OncoVEXGMCSF

 

 

OSI-906

 

 

OSU-03012, AR-12

 

 

OSU-HDAC42, s-HDAC-42, NSC D736012, AR-42

 

 

PF-2341066, PF-2,341,066, PF-02341066, PF1066, PF-1066

 

Crizotinib

PF-3446962, PF-3,446,962, PF-03446962

 

 

PI-88

 

Muparfostat

PM-10450, PM00104

Zalypsis

 

PRO70769, R1594

 

Ocrelizumab

PTC-210

 

 

PTC299

 

 

PX-478

 

 

PX-866, PX866

 

 

R1507, RG1507, formerly Roche 1

 

 

SAR3419

 

 

SAR650984

 

 

SCH 717454

 

 

Series PG500, PG545

 

 

SGN-35, SGN35

 

Brentuximab vedotin

SKI-606

 

Bosutinib

SL-052, SL052

 

Hypocrellin B

SL-052, SL052

 

Hypocrellin B

SNS-595, SPC-595 (formerly AG-7352)

 

Voreloxin

SOM230, SOM230C

 

Pasireotide

Specifid, formerly FavId

 

Imitumprotimut-T

SRT501

 

 

STA-9090

 

 

Sym004

 

 

VEGF Trap, VEGF-Trap, AVE0005, NSC 724770

 

Aflibercept

VGX-3100

 

 

WX-G250, anti-G250, cG250

Rencarex

 

XL184, XL 184, EXEL-7184, BMS 907351

 

 

XL765

 

 

XL880, XL-880, GSK1363089, GSK089

 

Foretinib

XMT-1001, MER-1001

 

 

ZD6474, AZD6474, AZD-6474

Zactima

Vandetanib

ZK-BA, 131-I-MIP-1145

Solazed

Ioflubenzamide I-131

[18F]-ML-10

ApoSense

 

  

Home   |    Freelance Opportunities   |   New Medicine   |   Site Map   |  Order/Inquiry   
SUBSCRIBER SEARCH:   NEW DRUG   |   MARKETED DRUG   |   COMPANY   |   TARGETS IN ONCOLOGY  

NEW MEDICINE, INC.
P.O. BOX 909, LAKE FOREST, CA 92609
PHONE:  1-949-830-0448     FAX:  1-949-830-0887
INFO@NEWMEDINC.COM